載入中
NASDAQHealthcareBiotechnology
最新資料
US$7.47
−US$0.03 · -0.40%
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
前收盤價
US$7.47
−US$0.03 · -0.40%
盤中時間採用ET。市場資料可能有所延遲。
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
日內區間
目前US$7.47
52週區間
目前US$7.47
盤中時間採用ET。市場資料可能有所延遲。
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
日內區間
目前US$7.47
52週區間
目前US$7.47
| 項目（USD） | 2025會計年度 |
|---|---|
| 銷貨成本 | 2417.6萬 USD |
| 毛利 | −2417.6萬 USD |
| 研究與開發 | 2.5億 USD |
| 銷售、一般及管理費用 | 8862.7萬 USD |
| 營業費用 | 3.15億 USD |
| 利息收入 | 1556.6萬 USD |
| 利息支出 | 83.7萬 USD |
| 折舊和攤銷 | 2417.6萬 USD |
| 營業利益 | −3.39億 USD |
| 淨利 | −3.24億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI690.48萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM617.66萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF252.19萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO151.19萬0.01%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO130.73萬0.01%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA114.77萬0.01%218.24億 USD0.03%US$32.79+0.40%
iShares Micro-Cap ETFIWC75.15萬0.06%13.17億 USD0.60%US$183+0.11%
ALPS Medical Breakthroughs ETFSBIO51.01萬0.27%1.91億 USD0.50%US$55.04+2.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
